Silencing IL-17 production in AD mice through AAV intracranial injection resulted in amelioration of AD symptoms and a significant increase of ABCA1 (181), which is a transporter of Aβ from brain to blood. This evidence concerns the gene ABCA1 and Alzheimer disease.